A review of clinical aspects of breast cancer

International Review of Psychiatry

Volumn 26, Issue 1, 2014, Pages 4-15

  Libson, Shai ^a   Lippman, Marc ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CLINICAL DECISION MAKING; CLINICAL FEATURE; HEALTH CARE QUALITY; HEREDITY; HUMAN; METASTASIS; MORBIDITY; PATHOGENESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE; SYSTEMIC THERAPY; WIDE EXCISION; BREAST NEOPLASMS; FEMALE; METABOLISM;

BREAST NEOPLASMS; FEMALE; HUMANS;

EID: 84896873829     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.3109/09540261.2013.852971     Document Type: Review

References (61)

1. Aebi, S (2012). Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent Breast Cancer; IBCSG 27-02, NSABP B-37, BIG 1-02). Paper presented at the San Antonio Breast Cancer Symposium, 6 December 2012, Abstract S3-2
2. Anderson, G.L., Chlebowski, R.T., Aragaki, A.K., Kuller, L.H., Manson, J.E., Gass, M., Wactawski-Wende, J. (2012). Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: Extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncology, 13, 476-486
3. Antoniou, A.C., Hardy, R., Walker, L., Evans, D.G., Shenton, A., Eeles, R., Pharoah, P.D. (2008). Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: Validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. Journal of Medical Genetics, 45, 425-431
4. Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.M., Freyer, G., Pujade-Lauraine, E. (2012). Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. Journal of Clinical Oncology, 30, 2718-2724
5. Baselga, J., Cort é s, J., Kim, S.B., Im, S.A., Hegg, R., Im, Y.H., CLEOPATRA Study Group. (2012a). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. New England Journal of Medicine, 366, 109-119
6. Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., NeoALTTO Study Team. (2012b). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet, 379, 633-640
7. Bentzen, S.M., Agrawal, R.K., Aird, E.G., Barrett, J.M., Barrett-Lee, P.J., Yarnold, J.R. (2008a). The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: A randomized trial. Lancet Oncology, 9, 331-341
8. Bentzen, S.M., Agrawal, R.K., Aird, E.G., Barrett, J.M., Barrett-Lee, P.J., Yarnold, J.R. (2008b). The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: A randomized trial. Lancet, 371, 1098-1107
9. Beaver, J.A. & Park, B.H. (2012). The BOLERO-2 trial: The addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncology, 8, 651-657
10. Berry, D.A., Iversen, E.S. Jr, Gudbjartsson, D.F., Hiller, E.H., Garber, J.E., Peshkin, B.N., Parmigiani, G. (2002). BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. Journal of Clinical Oncology, 20, 2701-2712
11. Blackwell, K.L., Burstein, H.J., Storniolo, A.M., Rugo, H., Sledge, G., Koehler, M., O Shaughnessy, J. (2010). Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumabrefractory metastatic breast cancer. Journal of Clinical Oncology, 28, 1124-1130
12. Bleyer, A. & Welch, H.G. (2012). Effect of three decades of screening mammography on breast-cancer incidence. New England Journal of Medicine, 367, 1998-2005
13. Chlebowski, R.T., Kuller, L.H., Prentice, R.L., Stefanick, M.L., Manson, JE ., Gass, M., Anderson, G.W. (2009). Breast cancer after use of estrogen plus progestin in postmenopausal women. New England Journal of Medicine, 360, 573-587
14. Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., Evans, E., Wang, Y. (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet, 366, 2087-2106
15. Colditz, G.A. & Rosner, B. (2000). Cumulative risk of breast cancer to age 70 years according to risk factor status: Data from the Nurses Health Study. American Journal of Epidemiology, 152, 950-964
16. Coombes, R.C., Kilburn, L.S., Snowdon, C.F., Paridaens, R., Coleman, R.E., Jones, S.E., Bliss, J.M. (2007). Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): A randomized controlled trial. Lancet, 369, 559-570
17. Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M. & Forbes, J.F. (2010). Effect of anastrozole and tamoxifen as adjuvant treatment for early stage breast cancer: 10 year analysis of ATAC trail. Lancet Oncology, 11, 1135-1141
18. Darby, S.C., Ewertz, M., McGale, P., Bennet, AM ., Blom-Goldman, U., Br ø nnum, D., Hall, P. (2013). Risk of ischemic heart disease in women after radiotherapy for breast cancer. New England Journal of Medicine, 368, 987-998
19. Darby, S., McGale, P., Correa, C., Taylor, C., Arriagada, R., Clarke, M., Peto, R. (2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-Analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet, 378, 1707-1716
20. Dawson, S.J., Rueda, O.M., Aparicio, S. & Caldas, C. (2013). A new genome-driven integrated classifi cation of breast cancer and its implications. European Molecular Biology Organization Journal, 32, 617-628
21. Early Breast Cancer Trialists Collaborative Group (EBCTCG). (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet, 365, 1687-1717
22. Euhus, D.M. & Robinson, L. (2013). Genetic predisposition syndromes and their management. Surgical Clinics of North America, 93, 341-362
23. Eifel, P., Axelson, J.A., Costa, J., Crowley, J., Curran, W.J. Jr ., Deshler, A., Roter, D. (2001). National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. Journal of the National Cancer Institute, 93, 979-989
24. Fisher, B., Costantino, J.P., Wickerham, D.L., Redmond, C.K., Kavanah, M., Cronin, W.M., Wolmark, N. (1998). Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute, 90, 1371-1388
25. Fisher, B., Montague, E., Redmond, C., Deutsch, M., Brown, GR ., Zauber, A., Wong, A. (1980). Findings from NSABP Protocol No. B-04-comparison of radical mastectomy with alternative treatments for primary breast cancer. Cancer, 46, 1-13
26. Fisher, B., Anderson, S., Bryant, J., Margolese, R.G., Deutsch, M., Fisher, E.R., Wolmark, N. (2002). Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New England Journal of Medicine, 347, 1233-1241
27. Gail, M.H., Brinton, L.A., Byar, D.P., Corle, D.K., Green, S.B., Schairer, C. & Mulvihill, J.J. (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. Journal of the National Cancer Institute, 81, 1879-1886
28. Gianni, L., Pienkowski, T., Im, Y.H., Roman, L., Tseng, L.M., Liu, M.C., Valagussa, P. (2012). Effi cacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, infl ammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncololgy, 13, 25-32
29. Giuliano, A.E., Kirgan, D.M., Guenther, J.M. & Morton, D.L. (1994). Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Annals of Surgery, 220, 391-398; discussion 398 -401
30. Giuliano, A.E., Hunt, K.K., Ballman, K.V., Beitsch, P.D., Whitworth, P.W., Blumencranz, P.W., Morrow, M. (2011). Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. Journal of the American Medical Association, 305, 569-575
31. Goodwin, J.S., Zhang, D.D. & Ostir, G.V. (2004). Effect of depression on diagnosis, treatment, and survival of older women with breast cancer. Journal of the American Geriatrics Society, 52, 106-111
32. Goss, P.E, Ingle, J.N., Pater, J.L., Martino, S., Robert, N.J., Muss, H.B. & Tu, D. (2008). Late extended adjuvant treatment with letrozole improves outcome in women with early stage breast cancer who complete 5 years of tamoxifen. Journal of Clinical Oncology, 26, 1948-1955
33. Harvie, M., Hooper, L. & Howell, A.H. (2003). Central obesity and breast cancer risk: A systematic review. Obesity Review, 4, 157-173
34. Hancock, S.L., Tucker, M.A. & Hoppe, R.T. (1993). Breast cancer after treatment of Hodgkin s disease. Journal of the National Cancer Institute, 85, 25-31
35. Halsted, W.S. (1894). The Results of Operations for the Cure of Cancer of the Breast Performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Annals of Surgery, 20, 497-555
36. Hendrick, R.E., Smith, R.A., Rutledge, J.H. III & Smart, C.R. (1997). Benefi t of screening mammography in women aged 40-49: A new meta-Analysis of randomized controlled trials. Journal of the National Cancer Institute Monographs, 22, 87-92
37. Kaplan, H.G., Malmgren, J.A. & Atwood, M.K. (2011). Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: A registry cohort analysis 1990-2005. BMC Cancer, 11, 260
38. Krag, D.N., Anderson, S.J., Julian, T.B., Brown, A.M., Harlow, S.P., Costantino, J.P., Wolmark, N. (2010). Sentinellymph-node resection compared with conventional axillarylymph-node dissection in clinically node-negative patients with breast cancer: Overall survival fi ndings from the NSABP B-32 randomised phase 3 trial. Lancet Oncology, 11, 927-933
39. Kunkler, I.H., Canney, P., van Tienhoven, G. & Russell, N.S. (2008). Elucidating the role of chest wall irradiation in intermediate-risk breast cancer: The MRC/EORTC SUPREMO trial. Clinical Oncology, 20, 31-34
40. Mamounas, E.P., Bryant, J., Lembersky, B., Fehrenbacher, L., Sedlacek, S.M., Fisher, B,.Wolmark, N. (2005). Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. Journal of Clinical Oncology, 23, 3686-3696
41. Mansel, R.E., Fallowfi eld, L., Kissin, M., Goyal, A., Newcombe, R.G., Dixon, J.M., Ell, P.J. (2006). Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC trial. Journal of the National Cancer Institute, 98, 599-609
42. Miller, A.H., Maletic, V. & Raison, C.L. (2009). Infl ammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biological Psychiatry, 65, 732-741
43. Perou, C.M., S ø rlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, CA. & Botstein, D. (2000). Molecular portraits of human breast tumours. Nature, 406, 747-752
44. Peto, R., Davies, C., Godwin, J., Gray, R., Pan, H.C., Clarke, M., Costa, J. (2012). Comparisons between different polychemotherapy regimens for early breast cancer: Meta-Analyses of long-Term outcome among 100,000 women in 123 randomised trials. Lancet, 379, 432-444
45. Qin, Y.Y., Li, H., Guo, X.J., Ye, X.F., Wei, X., Zhou, Y.H., Lu, J., He, J. (2011). Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: A meta-Analysis of 19 randomized trials with 30698 patients. Plos ONE, 6, e26946
46. Richardson, H., Johnston, D. & Pater J. (2007). The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: An international breast cancer prevention trial. Current Oncology, 14, 89-96
47. Rimawi, M.F., Mayer, I.A., Forero, A., Nanda, R., Goetz, M.P., Rodriguez, A.A., Chang, J.C. (2013). Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. Journal of Clinical Oncology, 31, 1726-1731
48. Romond, E.H., Perez, E.A., Bryant, J., Suman, V.J., Geyer, C.E. Jr., Davidson, N.E. Wolmark, N. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine, 353, 1673-1684
49. Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M.O., Lehman, C.D. & Russell, C.A. (2007). American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography . CA: A Cancer Journal for Clinicians, 57, 75-89
50. Satin, J.R., Linden, W. & Phillips, M.J. (2009). Depression as a predictor of disease progression and mortality in cancer patients: A meta-Analysis. Cancer, 115, 5349-5361
51. Smith-Warner, S.A., Spiegelman, D., Yaun, S.S., van den Brandt, P.A., Folsom, A.R., Goldbohm R.A., Hunter, D.J. (1998). Alcohol and breast cancer in women: A pooled analysis of cohort studies. Journal of the American Medical Association, 279, 535-540
52. Solin, L.J., Gray, R., Baehner, F.L., Butler, S.M., Hughes, L.L., Yoshizawa, C., Badve, S. (2013). A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. Journal of the National Cancer Institute, 5, 701-710
53. Sparano, J.A. (2006). TAILORx: Trial assigning individualized options for treatment (Rx). Clinical Breast Cancer, 7, 347-350
54. Spiegel, D. & Giese-Davis, J. (2003). Depression and cancer: Mechanisms and disease progression. Biological Psychiatry, 54, 269-282
55. Straver, M.E., Meijnen, P., van Tienhoven, G., van de Velde, C.J., Mansel, R.E., Bogaerts, J., Rutgers, E.J. (2010). Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. Journal of Clinical Oncology, 28, 731-737
56. Th ürlimann, B., Keshaviah, A., Coates, A.S., Mouridsen, H., Mauriac, L., Forbes, J.F., Goldhirsch, A. (2005). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New England Journal of Medicine, 353, 2747-2757
57. Urban, J.A. (1963). Extended mastectomy for breast cancer. American Journal of Surgery, 106, 399-404
58. Verma, S., Miles, D., Gianni, L., Krop, I.E., Welslau, M., Baselga, J., EMILIA Study Group. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine, 367, 1783-1791
59. Wellings, S.R. & Jensen, H.M. (1973). On the origin and progression of ductal carcinoma in the human breast. Journal of the National Cancer Institute, 50, 1111-1118
60. Whelan, T.J., Pignol, J.P., Levine, M.N., Julian, J.A., MacKenzie, R., Parpia, S., Shelley, W. (2010). Long-Term results of hypofractionated radiation therapy for breast cancer. New England Journal of Medicine, 362, 513-520
61. Wolmark, N., Wang, J., Mamounas, E., Bryant, J. & Fisher, B. (2001). Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. Journal of National Cancer Institute Monograph, 30, 96-102